Free Trial

Oxford Biomedica (OXB) Competitors

Oxford Biomedica logo
GBX 412.50 0.00 (0.00%)
(As of 12:24 PM ET)

OXB vs. ONT, GNS, ERGO, SLN, PRTC, HZD, VRP, BVXP, ARIX, and 4BB

Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Bioventix (BVXP), Arix Bioscience (ARIX), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

Oxford Biomedica vs.

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.

Oxford Nanopore Technologies currently has a consensus price target of GBX 235.50, indicating a potential upside of 93.00%. Oxford Biomedica has a consensus price target of GBX 433.33, indicating a potential upside of 4.92%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford Biomedica
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.08% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-94.82% -26.08% -14.42%
Oxford Biomedica -145.98%-124.66%-12.67%

In the previous week, Oxford Nanopore Technologies and Oxford Nanopore Technologies both had 1 articles in the media. Oxford Nanopore Technologies' average media sentiment score of 1.21 beat Oxford Biomedica's score of 0.92 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Nanopore Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford Biomedica
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oxford Biomedica received 327 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

CompanyUnderperformOutperform
Oxford Nanopore TechnologiesOutperform Votes
32
100.00%
Underperform Votes
No Votes
Oxford BiomedicaOutperform Votes
359
66.73%
Underperform Votes
179
33.27%

38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are owned by institutional investors. 32.6% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 21.2% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£167.75M6.85-£159.06M-£0.20-610.10
Oxford Biomedica£97.28M4.47-£142.02M-£1.44-286.81

Oxford Nanopore Technologies has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Oxford Nanopore Technologies beats Oxford Biomedica on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OXB vs. The Competition

MetricOxford BiomedicaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£435.14M£164.86M£5.07B£1.39B
Dividend Yield4.57%3.25%4.99%11.73%
P/E Ratio-286.81329.4787.861,549.36
Price / Sales4.4714,996.691,228.82209,059.57
Price / Cash3.0111.6739.5132.93
Price / Book6.567.126.942.80
Net Income-£142.02M-£18.52M£119.12M£152.70M
7 Day Performance0.12%-0.22%-1.84%-0.51%
1 Month Performance-0.48%8.10%-3.65%7.11%
1 Year Performance115.10%26.08%31.64%91.82%

Oxford Biomedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OXB
Oxford Biomedica
0.9962 of 5 stars
GBX 412.50
flat
GBX 433.33
+5.1%
+113.7%£434.61M£97.28M-286.46891Gap Down
High Trading Volume
ONT
Oxford Nanopore Technologies
2.6671 of 5 stars
GBX 122.80
+0.3%
GBX 235.50
+91.8%
-38.5%£1.16B£167.75M-612.001,281News Coverage
Positive News
High Trading Volume
GNS
Genus
2.1452 of 5 stars
GBX 1,644
-2.5%
GBX 2,150
+30.8%
-24.0%£1.08B£668.80M14,050.00480
ERGO
Ergomed
N/AGBX 1,346
flat
N/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AGBX 535
-0.9%
N/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
N/AGBX 162
+0.1%
N/A-5.6%£387.86M£3.33M-702.61300
HZD
Horizon Discovery Group plc (HZD.L)
N/AGBX 184.50
flat
N/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AGBX 55
+5.8%
N/A+0.0%£228MN/A-1.6822Gap Up
BVXP
Bioventix
N/AGBX 3,710
-1.1%
N/A-5.2%£193.66M£13.60M2,298.1612
ARIX
Arix Bioscience
N/AGBX 142
flat
N/A+29.1%£183.73M£14.16M1,290.919
4BB
4basebio
N/AGBX 1,310
+0.8%
N/A+146.8%£167.81M£311,000.00-1,666.67101Insider Trade
News Coverage

Related Companies and Tools


This page (LON:OXB) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners